Semaglutide alcohol use disorder data outpaces FDA endpoint framework
A Lancet trial in treatment-seeking patients with both alcohol use disorder and obesity leaves Novo Nordisk without a clear regulatory template for a Phase 3 program.
DO
By Daniel Okafor · Regulatory Correspondent
May 4 03:00 ETSource: The Clinical Trial Vanguard
The wire
- 01A Lancet trial of once-weekly semaglutide versus placebo in treatment-seeking patients with comorbid alcohol use disorder and obesity reported therapeutic effects across both conditions.
- 02The FDA qualified a two-level reduction in risk drinking level as an acceptable Phase 3 primary endpoint on February 14, 2025, but that framework does not address the comorbid AUD-obesity phenotype studied here.
- 03Any Phase 3 program must choose between broad AUD enrollment, which risks diluting effect, or a restricted comorbid population that complicates label generalization. No filing has been announced.
From the source
Read at clinicaltrialvanguard.comSemaglutide’s Alcohol Data Is Stronger Than Anyone Expected — and the FDA Has No Playbook for It
Pull up the Lancet trial on once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity, and the first thing that should hit you is not the effect size — it’s the population. These were treatment-seeking participants. People who wanted help. People whose obesity and alcohol use disorder were co-occurring at a clinical threshold. And semaglutide, a drug approve